11/01/2017 18:20:00

Deadline in Lawsuit for Investors in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced by Shareholders Foundation

Related content
09 Jan - 
Immunomedics Announces Reconstituted Board of Directors..
05 Jan - 
LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmace..
29 Dec - 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC R..

SAN DIEGO, Jan. 11, 2017 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline is coming up on January 17, 2017 in the lawsuit that was filed for certain investors in NASDAQ: LGND shares over alleged Securities Laws Violations by Ligand Pharmaceuticals Inc. 

The lawsuit seeks to recover damages for certain NASDAQ:LGND investors. 

Investors who purchased shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) have certain options and for certain investors there are short and strict deadlines running. Deadline: January 17, 2017. NASDAQ: LGND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. 

On November 9, 2016, Ligand Pharmaceuticals Inc. announced that it would not be able to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and that it was reviewing a potential restatement. 

On November 14, 2016, Ligand Pharmaceuticals Inc. announced that it would restate financial statements for the quarters ended September 30, 2015; December 31, 2015; March 31, 2016; and June 30, 2016, due to a material error. Ligand Pharmaceuticals Inc. also disclosed that its management determined that the Company did not maintain effective controls over the accuracy and presentation of accounting for income taxes related to complex transactions. 

On November 17, 2016, a lawsuit was filed against Ligand Pharmaceuticals Inc (NASDAQ:LGND) in the U.S. District Court for the Southern District of California. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that Ligand Pharmaceuticals Inc. overstated the value of certain Deferred Tax Assets by approximately $27.5 million or 13%, that Ligand Pharmaceuticals Inc.’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015, that Ligand Pharmaceuticals Inc. did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions, that in turn, Ligand Pharmaceuticals Inc. lacked effective internal control over financial reporting, and that as a result, defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. 

Those who purchased Ligand Pharmaceuticals Inc. (NASDAQ:LGND) shares should contact the Shareholders Foundation, Inc. 

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.

Michael Daniels

+1 (858) 779-1554

mail@shareholdersfoundation.com

3111 Camino Del Rio North

Suite 423

San Diego, CA 92108

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

G4S plc UK DK : Director/PDMR Shareholding

22/03/2017 15:45:39
22 March 2017 G4S PLC (the "Company") Notification and public disclosure of transactions by persons discharging managerial responsibilities ('PDMRs'). Vesting of shares under the 2014 Company's Long Term Incentive Plan ("LTIP") On 20 March 2017, the following ordinary shares in the Company were acquired by one executive director and nine other PDMRs within the Company, fol..

Alliance Trust PLC : Net Asset Value(s)

22/03/2017 13:23:08
ALLIANCE TRUST PLC                                    At the close of business on Tuesday 21 March 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 723.3p -       including income, 729.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding incom..

HSBC Bank Plc : Form 8.5 (EPT/RI) - Galliford Try PLC

22/03/2017 10:59:37
 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
The initial public offering of Next Games has been discontinued due to oversubscription
2
Metso honored with Best Foreign Entrepreneur 2016 award in South Korea
3
IMPORTANT ARGOS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Argos Therapeutics, Inc. in the Middle District of North Carolina
4
Avtec Inc. and Harris Corporation Announce New Strategic Alliance
5
IMPORTANT WALTER INVESTMENT MANAGEMENT CORPORATION INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that securities class action lawsuits have been filed against Walter Investment Management Corporation

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 March 2017 06:19:29
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170322.1 - EUROWEB3 - 2017-03-23 07:19:29 - 2017-03-23 06:19:29 - 1000 - Website: OKAY